**MDCG 2024-7**

**Preliminary assessment review template –**

**MDR (Regulation (EU) 2017/745)**

 **May 2024**

|  |  |
| --- | --- |
|  |  |
|  |

This document has been endorsed by the Medical Device Coordination Group (MDCG) established by Article 103 of Regulation (EU) 2017/745. The MDCG is composed of representatives of all Member States and it is chaired by a representative of the European Commission.

The document is not a European Commission document and it cannot be regarded as reflecting the official position of the European Commission. Any views expressed in this document are not legally binding and only the Court of Justice of the European Union can give binding interpretations of Union law.

### **Preliminary assessment review template[[1]](#footnote-1)- MDR** **(Regulation (EU) 2017/745)**

|  |
| --- |
| **DETAILS ON THE APPLICATION AND THE REVIEWERS** |
| Name and (if applicable) identification number of Conformity Assessment Body (CAB) |  |
| Name of Designating Authority (DA) |  |
| DA’s reference number(s) |  |
| Purpose of the application | ☐ Initial Designation |
| ☐ Extension of the scope of designation | Codes and/or conformity assessment activities (if applicable) to be added[[2]](#footnote-2): |
| Date the application was received by DA[[3]](#footnote-3) |  |
| Languages in which the application and supporting documents were provided |  |
| Date on which the application has been sent to the European Commission together with the completeness check form  |  |
| Name of the reviewer(s)[[4]](#footnote-4) |  |
| Date(s) of the review |  |
| In case the form is used by the DA for intermediate stages of the review, date(s) of previous review(s)/report(s) on this application |  |

|  |
| --- |
| **OUTCOME OF THE REVIEW[[5]](#footnote-5)** |
| On the basis of the documents received should it be envisaged to conduct an onsite assessment? | [ ]  Yes[ ]  Yes, with issues described below to be clarified during the on-site assessment | Indicate proposed on-site assessment dates: |
| ☐ No, the deficiencies described below have to be clarified before an onsite assessment can be envisaged[[6]](#footnote-6) |
| DA’s general comments on the application, if applicable |  |

|  |
| --- |
| **REVIEW OF THE APPLICATION** |

|  |
| --- |
| **G. GENERAL DOCUMENTATION**  |
| **List of comments on single documents****[[7]](#footnote-7)** |
| G.1 Scope of designation requested under the MDR |
| MDCG 2021-17 | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| G.2 Authorisation to represent the conformity assessment body by the person who has submitted the application on behalf of the body, unless such authorisation follows from the documentation specified in point 1.1.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| G.3 Valid accreditation certificate and the corresponding evaluation report as referred to in Article 38(2) of Regulation (EU) 2017/745 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| G.4 Compliance strategy explaining how the requirements set out in Annex VII of Regulation (EU) 2017/745 have been fulfilled, including, in the case of notified bodies designated under Council Directive 90/385/EEC and/or Council Directive 93/42/EEC, a gap analysis explaining how the alignment to the new requirements of the Regulations has been achieved |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **1. ORGANISATIONAL AND GENERAL REQUIREMENTS** |
| **List of comments on single documents**7 |
| **1.1 Legal status and organisational structure** |
| 1.1.1 Annex VII  | Documentation detailing the conformity assessment body’s legal personality and its status, including information about ownership and the legal or natural persons exercising control over the conformity assessment body | MDCG 2019-6[[8]](#footnote-8)Q I.2 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 1.1.2 Annex VII | Documentation detailing the activities of the organisation to which the conformity assessment body belongs, the organisational structure and governance of that organisation, and its relationship with the conformity assessment body | MDCG 2019-6Q I.3Q I.4 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 1.1.3Annex VII | Documentation detailing the activities and responsibilities of any legal entity which is wholly or partly owned by the conformity assessment body or which wholly or partly owns the conformity assessment body, and the legal and operational relationships with the conformity assessment body |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 1.1.4 -1.1.5 Annex VII  | Documentation describing the organisational structure, the allocation of responsibilities, reporting lines and the operational management conformity assessment body | MDCG 2019-6Q I.4 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 1.1.6 Annex VII  | Documentation detailing the functions, responsibilities and authorities of the top-level management, indicating the overall authority and responsible person for each of the following: |
| Provision of adequate resources for conformity assessment activities | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Development of procedures and policies for the operation of the notified body | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Supervision of implementation of the procedures, policies and quality management systems of the notified body | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Supervision of the notified body's finances | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Activities and decisions taken by the notified body, including contractual agreements | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Delegation of authority to personnel and/or committees, where necessary, for the performance of defined activities | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Interaction with the authority responsible for notified bodies and the obligations regarding communications with other competent authorities, the Commission and other notified bodies | *Responsible person (position or role, no individual name)**Relevant documents and Comment* |
| Individual having overall responsibility for all conformity assessment activities in relation to devices (head of the notified body) | *Responsible person (position or role, no individual name)**Relevant documents and Comment* | Annex VII3.1.1Last paragraph |
| **1.2 Independence and impartiality** |
| 1.2.1 -1.2.2Annex VII | Documentation detailing the structures, policies and procedures the conformity assessment body has in place to safeguard and promote the principles of independence, impartiality and objectivity throughout its whole organisation (e.g. corporate group), personnel and activities, including procedures providing for the identification, investigation and resolution of any case in which a conflict of interest may arise | Annex VII 1.1.2 |
| MDCG 2019-6 Q I.3Q I.4Q I.5Q I.9 |
| *Personnel commitment and written statement* | *Comment* | Annex VII2.4 |
| *Title and Revision Document 2* | *Comment* |
| 1.2.3 - 1.2.7Annex VII  | Independence of the notified body, the larger organisation to which it belongs, the top-level management and conformity assessment personnel Documentation on ensuring independence and impartiality with respect to:- Medical device industry (1.2.3)- Consultancy activities (1.2.3 - 1.2.4)- Remuneration (1.2.5)- Declarations of interest by top-level management (1.2.5)- Public ownership (1.2.6)- Subsidiaries,subcontractors and external experts (1.2.7; 3.4.2) | Article 53.5Annex VII1.1.21.2.92.4 |
| MDCG 2019-6Q I.3Q I.4Q I.5Q I.6Q I.8Q I.9 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 1.2.8 Annex VII  | Documentation demonstrating how the conformity assessment body operates with a set of consistent, fair and reasonable terms and conditions, taking into account small and medium size businesses |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **1.3 Confidentiality** |
| 1.3.1 - 1.3.2 Annex VII  | Documentation detailing how the conformity assessment body ensures that its personnel, committees, subsidiaries, subcontractors, and any associated body or personnel of external bodies respect the confidentiality and secrecy of the information (including proprietary rights) which comes into their possession  |
| *Personnel commitment and written statement* | *Comment* | Annex VII2.4; 3.4.2 |
| *Title and Revision Document 2* | *Comment* |
| **1.4 Liability** |
| 1.4.1 - 1.4.2 Annex VII | Documentation on the liability insurance covering conformity assessment activities, including its scope and overall financial value | MDCG 2019-6Q I.10 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **1.5 Financial requirements** |
| 1.5Annex VII  | Documentation detailing the conformity assessment body’s financial resources, including its financial capacity and long-term economic viability |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **1.6 Participation in coordination activities** |
| 1.6.1 - 1.6.2 Annex VII | Documentation on the CAB’s procedures ensuring its personnel is involved in standardisation activities and in the work of the notified body coordination group and how personnel are informed. Strategy to take into consideration guidance and best practice documents | Article 49 |
| MDCG 2019-6 Q I.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |

|  |
| --- |
| **2. QUALITY MANAGEMENT REQUIREMENTS** |
| **List of comments on single documents[[9]](#footnote-9)** |
| 2.1 - 2.2 first indentAnnex VII | Management system structure and the list of all quality management system documents, including policies and objectives | Annex VII4.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 second indentAnnex VII | Policies for assignment of activities and responsibilities to personnel |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 third indentAnnex VII | Documentation detailing the assessment and decision-making processes in accordance with the tasks, responsibilities and role of the notified body's personnel and top-level management |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 fourth indentAnnex VII | Documentation detailing the planning, conduct, evaluation and, if necessary, adaptation of the conformity assessment procedures |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 fifth indentAnnex VII | Procedures for control of documents including verification that the documents have the same content where documents are used in different languages | Annex VII2.2Last paragraph |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 sixth indentAnnex VII | Procedures for control of records |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 seventh indentAnnex VII | Procedures for management review |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 eighth indentAnnex VII | Procedures for internal audits  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 ninth indentAnnex VII | Procedures for corrective and preventive actions |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 tenth indentAnnex VII | Procedures for complaints and appeals |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.2 eleventh indentAnnex VII | Procedures for continuous training | Annex VII3.1.23.5.2 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.3Annex VII | Documentation relating to the implementation and maintenance of the quality management system throughout the conformity assessment body’s organisation, including subsidiaries and subcontractors involved in conformity assessment activities |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 2.4Annex VII | Model declaration of commitment of the CAB’s personnel to comply with the procedures  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Articles 36.244.244.3 | Procedures on the NB’s obligation to make available and submit upon requests all relevant documentation  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Articles 44.146.346.546.9 | Procedures on the NB’s obligation for information in case of relevant changes and ceasing of activities  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |

|  |
| --- |
| **3. RESOURCE REQUIREMENTS** |
| **List of comments on single documents[[10]](#footnote-10)** |
| **3.1 General** |
| 3.1.1Annex VII | Documentation detailing the CAB’s:- Equipment, facilities and competence (including testing facilities) needed to perform properly the technical, scientific and administrative tasks- Permanent availability of personnel and in sufficient numbers, including templates of employment and other contracts used for the personnel- Sufficient internal competence to critically evaluate assessments conducted by external expertise (3.4.3) | Article 36.1 |
| MDCG 2019-6 Q III.2Q III.3 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.1.2Annex VII | Documentation detailing the implementation of a system for exchange of experience and a continuous training and education programme |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.1.3Annex VII | Documentation detailing:- The extent and limits of duties and responsibilities of the personnel, including subcontractors and external experts- The level of authorisation of the personnel- The process for information the personnel accordingly |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **3.2 Qualification criteria in relation to personnel** |
| 3.2.1 - 3.2.2Annex VII | Documentation detailing:- Process to establish and document the qualification criteria (providing a sufficient level of detail for the required qualification within the subdivisions of the applied-for scope)- Process for selection and authorisation of personnel, including the required initial and ongoing training | NBOG BPG 2017-2 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.2.2 - 3.2.7Annex VII | - Specific qualification criteria (3.2.2)Qualification criteria per role:- Personnel responsible for establishing qualification criteria and for authorising other personnel (3.2.3)- Personnel with relevant clinical expertise (Internal clinician/Clinical specialist) (3.2.4)- Product reviewers (3.2.5)- Site auditors (3.2.6)- Final reviewers and decision-makers (3.2.7) | Article 36.1 (employed by) |
| NBOG BPG 2017-2 |
| MDCG 2019-6 Q III.4Q III.6Q III.7Q IV.6 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **3.3 Documentation of qualification, training and authorisation of personnel** |
| 3.3.1Annex VII | Procedure in place to fully document the qualification of each member of personnel and the satisfaction of the qualification criteria | NBOG BPG 2017-2 |
| MDCG 2019-6Q III.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.3.2 first indentAnnex VII  | Matrix detailing the authorisations (including any limitations) and responsibilities of the personnel, including employment status (e.g. full-time, external, etc.) and location of all internal and external personnel; the authorisations shall be specified by using the codes set out in the [Commission Implementing Regulation on codes and corresponding types of devices](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2017.309.01.0007.01.ENG&toc=OJ:L:2017:309:TOC) | MDCG 2019-14 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.3.2 second indentAnnex VII  | Model/template of the record attesting authorisation of qualified personnel; the records shall contain a rationale for defining the scope of the responsibilities for each of the assessment personnel and records of the conformity assessment activities carried out by each of themRepresentative sample of records (at least one per role/function) demonstrating compliance with the qualification criteria for the authorisation of the personnel member (mock file or blacked out document might be acceptable) |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **3.4 Subcontractors and external experts** |
| 3.4.1Annex VII | Lists of all subcontractors and subsidiaries, including a description of their functions in relation to conformity assessment activities (e.g. external laboratories) or administrative tasks (e.g. information technologies) and contractual arrangements in place | Article 37Article 57(a)  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 3.4.2Annex VII | Documentation detailing the conditions under which subcontracting may take place |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **3.5 Monitoring of competences, training, exchange of experience** |
| 3.5.1 - 3.5.2Annex VII | Documentation detailing:-The initial evaluation, on-going monitoring and periodic review of competence of the internal and external personnel, including the identification of training needs and drawing up of training plans- How the personnel is aware of Union and national law in force on devices, relevant harmonised standards, CS, guidance documents and the results of the coordination activities of NBCG-Med- Verification that personnel takes part in the internal exchange of experience and the continuous training and education programme | Article 49 |
| MDCG 2019-6Q III.5 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |

|  |
| --- |
| **4. PROCESS REQUIREMENTS** |
| **List of comments on single documents[[11]](#footnote-11)** |
| **4.1 General** |
| 4.11st paragraphAnnex VII | Overview of processes for the conduct of each conformity assessment activity comprising the individual steps from pre-application activities up to decision-making and surveillance, e.g. flowcharts | Annex VII2.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.12nd paragraphAnnex VII | Documentation detailing the internal activities of the CAB which shall not be subcontracted | MDCG 2019-6Q III.6 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.2 Notified body quotations and pre-application activities** |
| 4.2 (a)Annex VII | Description of the application procedure by which manufacturers can obtain certification, including which languages are acceptable | MDCG 2019-6Q I.6 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.2 (b)Annex VII | Procedures relating to fees charged and financial conditions | Article 50 |
| MDCG 2019-6Q V.2 |
| MDCG 2023-2 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.2 (c)Annex VII | Procedures in relation to advertising of conformity assessment services |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.2 (d)Annex VII | Procedures relating to the review of pre-application information | Manual on borderline and classification |
| MDCG 2021-24 |
| MDCG 2022-5 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.2 (e)Annex VII | Procedures to ensure that all contracts relating to the conformity assessment activities are concluded directly between the manufacturer and the conformity assessment body |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.3 Application review and contract** |
| 4.31st paragraphAnnex VII | Template application form | MDCG 2019-6Q I.7 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.32nd paragraphAnnex VII | Template contract including terms and conditions and obligations of the CAB in relation to conformity assessment activities (terms and conditions might be in a separate annex to the contract template) |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.3 (a) – (e)Annex VII | Procedures relating to review of applications, including documented outcome of each review and notification to EUDAMED of refusals or withdrawals of applications | Article 53.2Application sections in Annex IX-XI |
| MDCG 2021-1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.4 Allocation of resources** |
| 4.41st and 2nd paragraphAnnex VII  | Procedures and forms to ensure that conformity assessment activities are conducted by appropriately qualified and authorised personnel, and that allocation of tasks and changes thereto are documented | Annex VII4.5.1 second indent  |
| MDCG 2019-6 Q IV.6Q IV.7 |
| MDCG 2019-14 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.42nd paragraphAnnex VII | Procedures and forms to identify one individual responsible for each application | MDCG 2019-6Q IV.7 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5 Conformity assessment activities** |
| 4.5.1 first indentAnnex VII | Procedures for planning the conduct of each individual project  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1 second indent Annex VII | Procedures for the rotation of the members of the assessment team at appropriate intervals | Annex IX3.6 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1third indentAnnex VII | Procedures specifying the rationale for fixing time limits for completion of the conformity assessment |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1Fourth to sixth indentsAnnex VII | Procedures for the assessment of the manufacturer's technical documentation including review of manufacturer's procedures and documentation relating to the evaluation of pre-clinical aspects and relating to clinical evaluation | Annex VII4.5.34.5.44.5.5 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1 seventh indent Annex VII | Procedures for the assessment of the interface between the manufacturer’s risk management process and its appraisal and analysis of the pre-clinical and clinical evaluation |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1eighth indent Annex VII | Procedures to carry out the specific procedures referred to in Sections 5.2 to 5.4 of Annex IX  |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1ninth indent Annex VII | In the case of class IIa or class IIb devices, procedures to assess the technical documentation of devices selected on a representative basis | Article 52Annex VII4.5.2Annex IX2.33.5 |
| MDCG 2019-13 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1tenth and eleventh indents Annex VII | Procedures to plan and periodically carry out appropriate surveillance audits and assessments, carry out or request certain tests to verify the proper functioning of the quality management system, to perform unannounced on site audits, and to verify that the manufactured device is in conformity with the technical documentation | Annex VII4.10 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1twelfth indent Annex VII | Procedures to evaluate and verify a manufacturer's compliance with relevant Annexes |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.1Last paragraph Annex VII | Procedures to take into consideration available CS, guidance and best practice documents and harmonised standards | MDCG 2019-6Q IV.11 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5.2 Quality management system auditing** |
| 4.5.2Annex VII | Procedures for the assessment of quality management systems, according to each specific conformity assessment activity covered by the application and the class of the device, including:- Drawing-up audit programmes- Auditing the various manufacturing sites, suppliers and/or subcontractors- Drawing-up audit plans- Drawing-up sampling plans for classes IIa and IIb- Selection of site auditors | Annex IX Chapter I |
| MDCG 2019-6Q IV.2 |
| MDCG 2019-13 |
| MDCG 2022-17 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5.3. Product verification** |
| 4.5.3Assessment of the technical documentation Annex VII | Procedures to assess the manufacturer’s technical documentation, including:- Allocations of personnel- Conformity of the design- Examination of the implementation by manufacturers of incoming, in-process and final checks- Physical or laboratory tests, if required | Article 52Annex IIAnnex IIIAnnex IX Chapter II |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.3Type-examinationsAnnex VII | Procedures to examine and assess the manufacturer’s technical documentation and verify the type, including establishment of tests plans | Annex X |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| 4.5.3Verification by examination and testing of every productAnnex VII | Documentation relating to verification by examination and testing of every product, including establishment of test plans | Annex XI (B) |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5.4 Pre-clinical evaluation assessment** |
| 4.5.4Annex VII | Procedures for the review of the manufacturer’s procedures and documentation relating to the evaluation of pre-clinical aspects | Annex II6.1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5.5 Clinical evaluation assessment** |
| 4.5.5Annex VII | Procedures for the review of the manufacturer’s procedures and documentation relating to clinical evaluation, including the validation of the summary of safety and clinical performance (for implantable and class III) and the upload of the summary to EUDAMED | Article 32Article 61Annex II6.1Annex XIV |
| MDCG 2019-9 |
| MDCG 2020-5 |
| MDCG 2020-6 |
| MDCG 2021-1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.5.6 Specific Procedures** |
| 4.5.6Annex VII  | Documentation relating to documented procedures, expertise and facilities to carry out the specific procedures:- Consultation to expert panel (5.1 Annex IX)- Consultation to medicinal products authority (5.2 and 5.4 Annex IX)- Consultation to human tissues and cells competent authority (5.3.1 Annex IX)- Preparation of a summary evaluation report for devices manufactured utilising TSE susceptible tissues or cells of animal origin (5.3.2 Annex IX)- Batch verification for derivatives from human blood or human plasma (6 Annex IX and 16 Annex XI) | Articles 54 and 55Annex IXSections 5 and 6Annex XSection 6Annex XISection 16 |
| Regulation 722/2012 |
| MDCG 2019-3 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.6 Reporting** |
| 4.6Annex VII | Documentation detailing how all steps of the conformity assessment are documented and relevant templates of reports/records, in particular:- Records related to QMS audits- Technical Documentation Assessment Report (TDAR)- Clinical Evaluation Assessment report (CEAR)- Detailed report for each specific project, including the recommendation for a final review and for a final decision- Procedure to provide the report to the manufacturer in question | MDCG 2020-13 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.7 Final review**  |
| 4.7Annex VII | Documentation relating to the final review process carried out prior to making a final decision |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.8 Decisions and Certifications** |
| 4.8Annex VII | Documentation relating to the final decision process, including:- Procedures for decision-making for the issuance, suspension, restriction and withdrawal of certificates- Certificate templates intended to be used for the different types of conformity assessments for which the CAB seeks designation- Notification of the outcome of the assessment and the resultant decision to the manufacturer and EUDAMED | Articles 56 and 57(g)Annex XII |
| MDCG 2018-8 |
| MDCG 2019-6Q IV.3Q IV.6Q IV.8 |
| MDCG 2021-1 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.9 Changes and modifications** |
| 4.9Annex VII | Documentation detailing manufacturers’ information obligations and the CAB’s assessment of changes, including documented procedures and contractual arrangements | MDCG 2019-6Q IV.9 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.10 Surveillance activities and post-certification monitoring** |
| 4.10 Annex VII | Documentation detailing the following: |
| Screening | Procedures for screening of relevant sources of scientific and clinical data and post-market information relating to the scope of designation |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Surveillance activities | Procedures in relation to surveillance activities, in particular to:- Define how and when surveillance activities of manufacturers are to be conducted (on at least an annual basis)- Conduct unannounced on-site audits- Assessment of the documentation on vigilance, PMS and PMCF- Sample and test devices and technical documentation- Impose specific restrictions on the relevant certificate, or suspend or withdraw it | Annex IXSections 3.3 and 3.4Annex XISection 7  |
| MDCG 2019-6Q IV.10 |
| MDCG 2020-7 |
| MDCG 2020-8 |
| MDCG 2023-3 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Vigilance | Procedures to review vigilance data which the NB has access under Article 92(2) and estimating the impact on issued certificates, including the recording of the results of the evaluation and any decisions taken |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| PSUR | Documentation relating to the review of periodic safety update reports | Article 86 |
| MDCG 2022-21 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Conditions | Procedures related to conditions for certification |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| **4.11 Re-certification** |
| 4.11Annex VII | Documentation detailing the conduct of re-certification reviews and the renewal of certificates | MDCG 2019-6Q IV.12 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |
| Article 58 | Documentation relating to voluntary changes of a notified body | MDCG 2018-8 |
| MDCG 2019-6Q IV.4 |
| *Title and Revision Document 1* | *Comment* |
| *Title and Revision Document 2* | *Comment* |

1. This form will be used to document the review of the CAB´s application by the DA. This document might be used as a living document during different steps of the review once the completeness check has been concluded. Nevertheless, only the final version of this report should be sent to the European Commission either after all deficiencies which are obstacles for an onsite assessment have been clarified or in case the DA has made the final decision that an on-site assessment should not be conducted. The European Commission will only start the process of appointment of the Joint Assessment Team according to Article 39 (3) to the MDR after a final decision has been taken and documented by the DA in section “Outcome of the review” of the final version of the report. For details see MDCG 2022-13 Designation, re-assessment and notification of conformity assessment bodies and notified bodies. [↑](#footnote-ref-1)
2. In case of extension of the scope of designation, the completion of this form will be limited to the specific sections and information relevant to the extension of the scope of designation. For example, section 3 (Resources) should describe the changes to the matrix and personnel which support the addition of codes. For details see in MDCG 2022-13 section on Assessments relating to extension of the scope of the designation. [↑](#footnote-ref-2)
3. Supporting documents, including new or updated documents after the original application, may be listed in the Annex (List of Documents) and attached to this PAR form. [↑](#footnote-ref-3)
4. In case of use by more than one reviewer entries should be traceable, e.g. by prefacing each comment/section with the initials of the reviewer or by using different colors. [↑](#footnote-ref-4)
5. This section is to be filled in at the end of the review, once all of the documentation has been examined. [↑](#footnote-ref-5)
6. This report is only to be sent to the European Commission after all deficiencies which are obstacles for an onsite assessment have been clarified by the DA (or in case the DA has made the final decision that an onsite assessment should not be conducted). [↑](#footnote-ref-6)
7. Please restrict the text to issues to be clarified. A summary of the content of the documents or the fulfillment of criteria is not requested. Only (potential) nonconformities and questions to be clarified should be described. This needs to be detailed as much as possible. For each item, the respective section / paragraph of the documents should be indicated. [↑](#footnote-ref-7)
8. The third column refers to legal provisions (in MDR or other Union legislation) and MDCG guidance also applicable to the specific requirement in MDR Annex VII. [↑](#footnote-ref-8)
9. Please restrict the text to issues to be clarified. A summary of the content of the documents or the fulfillment of criteria is not requested. Only (potential) nonconformities and questions to be clarified should be described. This needs to be detailed as much as possible. For each item, the respective section / paragraph of the documents should be indicated. [↑](#footnote-ref-9)
10. Please restrict the text to issues to be clarified. A summary of the content of the documents or the fulfillment of criteria is not requested. Only (potential) nonconformities and questions to be clarified should be described. This needs to be detailed as much as possible. For each item, the respective section / paragraph of the documents should be indicated. [↑](#footnote-ref-10)
11. Please restrict the text to issues to be clarified. A summary of the content of the documents or the fulfillment of criteria is not requested. Only (potential) nonconformities and questions to be clarified should be described. This needs to be detailed as much as possible. For each item, the respective section / paragraph of the documents should be indicated. [↑](#footnote-ref-11)